Could FDA updates speed your early-phase trial?

A new year brings new breakthroughs — and 2026 is already setting the stage for faster, smarter, and more connected clinical research. From regulatory milestones to regional growth and operational innovation, this edition highlights what’s driving progress in early-phase development: RevBio receives

first-in-human · clinical research · regulatory · FDA · MedTech · biopharma

A new year brings new breakthroughs — and 2026 is already setting the stage for faster, smarter, and more connected clinical research. From regulatory milestones to regional growth and operational innovation, this edition highlights what’s driving progress in early-phase development:

RevBio receives FDA approval for its regenerative bone glue trial. Akari advances a novel ADC therapy to first-in-human testing. Abbott gains FDA clearance for a next-generation cardiac system. Croatia strengthens its position as a Balkan trial hub.

Begin the year energized by discoveries redefining the future of Medtech and Biopharma. 👇

← All Global Trial Accelerators editions · Contact bioaccess®